While RCT studies support the use of Omega-3 for other inflammatory diseases, such as rheumatoid arthritis and asthma, the data on its use in DED is limited and with efficacy and safety of the use of Omega-3 in treatment of DED.

The DREAM study will be the first large scale, multicenter, double masked randomized controlled trial (RCT) using Omega-3 for DED. Work done in our NEI planning established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).

varying outcomes and success rates. Most studies concerning Omega-3 and DED are small with data recorded from a single site, with different outcome measures and using varying combinations of Omega-3 and other fatty acids with short study duration and contrasting results.9 The NIH has called for increased evidence on efficacy and safety of supplements for chronic disease, including randomized clinical trials. The U.S. Department of Health & Human services has also noted that few trials have established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).

The DREAM study will be the first large scale, multicenter, double-masked randomized controlled trial (RCT) using Omega-3 for DED. Work done in our NEI planning established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm). The DREAM study will be the first large scale, multicenter, double masked randomized controlled trial (RCT) using Omega-3 for DED. Work done in our NEI planning established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).

Though there has been some success with use of anti-inflammatory therapies for DED, most of the current options are limited by risks or side-effects, leaving many DED patients with continued signs and symptoms. An anti-inflammatory nutritional supplement may provide an alternative therapy for many patients.

While RCT studies support the use of Omega-3 for other inflammatory diseases, such as rheumatoid arthritis and asthma, the data on its use in DED is limited and with varying outcomes and success rates. Most studies concerning Omega-3 and DED are small with data recorded from a single site, with different outcome measures and using varying combinations of Omega-3 and other fatty acids with short study duration and contrasting results.9 The NIH has called for increased evidence on efficacy and safety of supplements for chronic disease, including randomized clinical trials. The U.S. Department of Health & Human services has also noted that few trials have established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).

The DREAM study will be the first large scale, multicenter, double masked randomized controlled trial (RCT) using Omega-3 for DED. Work done in our NEI planning established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm). The U.S. Department of Health & Human services has also noted that few trials have established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).

Though there has been some success with use of anti-inflammatory therapies for DED, most of the current options are limited by risks or side-effects, leaving many DED patients with continued signs and symptoms. An anti-inflammatory nutritional supplement may provide an alternative therapy for many patients.

While RCT studies support the use of Omega-3 for other inflammatory diseases, such as rheumatoid arthritis and asthma, the data on its use in DED is limited and with varying outcomes and success rates. Most studies concerning Omega-3 and DED are small with data recorded from a single site, with different outcome measures and using varying combinations of Omega-3 and other fatty acids with short study duration and contrasting results.9 The NIH has called for increased evidence on efficacy and safety of supplements for chronic disease, including randomized clinical trials. The U.S. Department of Health & Human services has also noted that few trials have established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).

The DREAM study will be the first large scale, multicenter, double masked randomized controlled trial (RCT) using Omega-3 for DED. Work done in our NEI planning established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm). The DREAM study will be the first large scale, multicenter, double masked randomized controlled trial (RCT) using Omega-3 for DED. Work done in our NEI planning established the efficacy of supplements in chronic disease (http://www.ahrq.gov/clinic/tp/multivittp.htm).